



130217016M: 100 tests/kit
130617016M: 50 tests/kit
130717016M: 30 tests/kit

MAGLUMI® Anti-Cardiolipin IgM (CLIA)

INTENDED USE

The kit is an *in vitro* chemiluminescence immunoassay for the quantitative determination of Anti-Cardiolipin IgM (aCL IgM) in human serum and plasma using the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer and Biolumi series Integrated System, and the assay is used for an aid in the diagnosis of individuals with suspected or confirmed Antiphospholipid syndrome (APS) and Systemic Lupus Erythematoses (SLE).

SUMMARY

Antiphospholipid syndrome (APS), also known as Hughes syndrome, was reported for the first time in 1983 by Dr. Graham Hughes ¹. The antiphospholipid syndrome is a systemic autoimmune disease defined by thrombotic or obstetrical events that occur in patients with persistent antiphospholipid antibodies. Thrombotic antiphospholipid syndrome is characterized by venous, arterial, or microvascular thrombosis. Patients with catastrophic antiphospholipid syndrome present with thrombosis involving multiple organs ². APS is considered a primary autoimmune disease, but is often diagnosed as being secondary to other auto-immune diseases; 30-40% of patients with Systemic Lupus Erythematoses (SLE) also have APS, and APS can be diagnosed secondary to rheumatoid arthritis, systemic sclerosis, dermatomyositis or other autoimmune diseases³. Progression of Catastrophic antiphospholipid syndrome (CAPS) occurs in approximately 1% of patients with APS, whereby the patient is affected by thromboses mostly in small vessels, leading to multiorgan failure. CAPS is a very severe condition with high mortality ¹.

The antiphospholipid antibodies including anticardiolipin antibody (ACA), anti-β2-glycoprotein 1 (β2-GP1), and lupus anticoagulant (LA) are a heterogeneous group of autoantibodies reacting against phospholipids, phospholipid-protein complexes, and phospholipid-binding proteins. ACA is a group of heterogeneous antibodies that are classified into IgG, IgA and IgM ⁴. Anticardiolipin antibodies recognize the plasma glycoprotein β2-GP1 in complex with the anionic phospholipid cardiolipin ³.

APS requires the combination of at least one clinical APS criterion (thrombosis or pregnancy complications) and one laboratory criterion (medium to high serum/plasma antibody titers measured at an interval of at least 12 weeks) ⁵. Antibody detection encompasses LA and aCL of IgG and/or IgM (titer >the 99th percentile) or anti-β2-GP1 of IgG and/or IgM (titer >the 99th percentile) ⁵. Generally speaking, the aCL test is positive in about 80% of patients with APS ⁶. The IgA isotype is recommended for both aCL and anti-β2-GP1 when results of all other tests are negative and APS is still suspected ⁷.

TEST PRINCIPLE

Indirect Chemiluminescence Immunoassay.

The prediluted sample, buffer, magnetic microbeads coated with aCL antigen and β2-GP1 antigen are mixed thoroughly and incubated, performing a wash cycle after a precipitation in a magnetic field. ABEI labeled with anti-human IgM antibody are then added and incubated, reacting to form immuno-complexes. After precipitation in a magnetic field, the supernatant is decanted and then a wash cycle is performed. Subsequently, the Starter 1+2 are added to initiate a chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is proportional to the concentration of aCL IgM present in the sample.

REAGENTS

Kit Contents

Component	Description	100 tests/kit	50 tests/kit	30 tests/kit
Magnetic Microbeads	Magnetic microbeads coated with aCL antigen (~0.100 µg/mL) and β2-GP1 antigen (~3.00 µg/mL) in PBS buffer, NaN ₃ (<0.1%).	2.5 mL	1.5 mL	1.0 mL
Calibrator Low	A low concentration of aCL IgM in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Calibrator High	A high concentration of aCL IgM in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Buffer	BSA, NaN ₃ (<0.1%).	17.5 mL	9.5 mL	6.3 mL
ABEI Label	ABEI labeled with anti-human IgM antibody (~25.0 ng/mL) in Tris-HCl buffer, NaN ₃ (<0.1%).	22.5 mL	12.0 mL	7.8 mL
Diluent	PBS buffer, NaN ₃ (<0.1%).	25.0 mL	13.5 mL	8.0 mL
Control 1	A low concentration of aCL IgM (10.0 AU/mL) in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Control 2	A high concentration of aCL IgM (100 AU/mL) in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL

All reagents are provided ready-to-use.

Warnings and Precautions

- For *in vitro* diagnostic use.
- For professional use only.
- Exercise the normal precautions required for handling all laboratory reagents.
- Personal protective measures should be taken to prevent any part of the human body from contacting samples, reagents, and controls, and should comply with local operating requirements for the assay.
- A skillful technique and strict adherence to the package insert are necessary to obtain reliable results.
- Do not use kit beyond the expiration date indicated on the label.
- Do not interchange reagent components from different reagents or lots.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- All waste associated with biological samples, biological reagents and disposable materials used for the assay should be considered potentially infectious and should be disposed of in accordance with local guidelines.
- This product contains sodium azide. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. Immediately after disposal, flush with a large volume of water to prevent azide build-up. For additional information, see Safety Data Sheets available for professional user on request.

Note: If any serious incident has occurred in relation to the device, please report to Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) or our authorized representative and the competent authority of the Member State in which you are established.

Reagent Handling

- To avoid contamination, wear clean gloves when operating with a reagent kit and sample. When handling reagent kit, replace the gloves that have been in contact with samples, since introduction of samples will result in unreliable results.
- Do not use kit in malfunction conditions; e.g., the kit leaking at the sealing film or elsewhere, obviously turbid or precipitation is found in reagents (except for Magnetic Microbeads) or control value is out of the specified range repeatedly. When kit in malfunction conditions, please contact Snibe or our authorized distributor.
- To avoid evaporation of the liquid in the opened reagent kits in refrigerator, it is recommended that the opened reagent kits to be sealed with reagent seals contained within the packaging. The reagent seals are single use, and if more seals are needed, please contact Snibe or our authorized distributor.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts and have no effect on assay efficacy.
- Use always the same analyzer for an opened reagent integral.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- For further information about the reagent handling during system operation, please refer to Analyzer Operating Instructions.

Storage and Stability

- Do not freeze the integral reagents.
- Store the reagent kit upright to ensure complete availability of the magnetic microbeads.
- Protect from direct sunlight.

Stability of the Reagents	
Unopened at 2-8°C	until the stated expiration date

Opened at 2-8°C	6 weeks
On-board	4 weeks

Stability of Controls	
Unopened at 2-8°C	until the stated expiration date
Opened at 10-30°C	24 hours
Opened at 2-8°C	6 weeks
Frozen at -20°C	3 months
Frozen and thawed cycles	no more than 1 time

SPECIMEN COLLECTION AND PREPARATION

Specimen Types

Only the specimens listed below were tested and found acceptable.

Specimen Types	Collection Tubes
Serum	Tubes without additive/accessory, or tubes containing clot activator or clot activator with gel.
Plasma	K2-EDTA or Na-heparin

- The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. Follow tube manufacturers' instructions carefully when using collection tubes.

Specimen Conditions

- Do not use heat-inactivated samples or grossly hemolyzed/hyperlipidaemia specimens and specimens with obvious microbial contamination.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some serum specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the serum specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results.
- Samples must be free of fibrin and other particulate matter.
- To prevent cross contamination, use of disposable pipettes or pipette tips are recommended.

Preparation for Analysis

- Inspect all specimens for foam. Remove foam with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.
- Frozen specimens must be completely thawed before mixing. Mix thawed specimens thoroughly by low speed vortexing or by gently inverting. Visually inspect the specimens. If layering or stratification is observed, mix until specimens are visibly homogeneous. If specimens are not mixed thoroughly, inconsistent results may be obtained.
- Specimens should be free of fibrin, red blood cells, or other particulate matter. Such specimens may give reliable results and must be centrifuged prior to testing. Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- The sample volume required for a single determination of this assay is 10 µL.

Specimen Storage

Specimens removed from the separator, red blood cells or clot may be stored up to 6 hours at 10-30°C or 7 days at 2-8°C, or 3 months frozen at -20°C. Frozen specimens subjected to up to 1 freeze/thaw cycle have been evaluated.

Specimen Shipping

- Package and label specimens in compliance with applicable local regulations covering the transport of clinical specimens and infectious substances.
- Do not exceed the storage limitations listed above.

Specimen Dilution

- Samples, with aCL IgM concentrations above the analytical measuring interval, can be diluted with Diluent either by following automated dilution protocol or manual dilution procedure. The recommended dilution ratio is 1:20. The concentration of the diluted sample must be >20 AU/mL.
- For manual dilution, multiply the result by the dilution factor. For dilution by the analyzers, the analyzer software automatically takes the dilution into account when calculating the sample concentration.

PROCEDURE

Materials Provided

Anti-Cardiolipin IgM (CLIA) assay, control barcode labels.

Materials Required (But Not Provided)

- General laboratory equipment.
- Fully-auto chemiluminescence immunoassay analyzer Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X3, MAGLUMI X6, MAGLUMI X8, or Integrated System Biolumi 8000 and Biolumi CX8.
- Additional accessories of test required for the above analyzers include Reaction Module, Starter 1+2, Wash Concentrate, Light Check, Tip, and Reaction Cup. Specific accessories and accessories' specification for each model refer to corresponding Analyzer Operating Instructions.
- Please use accessories specified by Snibe to ensure the reliability of the test results.

Assay Procedure

Preparation of the Reagent

- Take the reagent kit out of the box and visually inspect the integral vials for leaking at the sealing film or elsewhere. If there is no leakage, please tear off the sealing film carefully.
- Open the reagent area door; hold the reagent handle to get the RFID label close to the RFID reader (for about 2s); the buzzer will beep; one beep sound indicates successful sensing.
- Keeping the reagent straight insert to the bottom along the blank reagent track.
- Observe whether the reagent information is displayed successfully in the software interface, otherwise repeat the above two steps.
- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are totally resuspended homogenous prior to use.

Assay Calibration

- Select the assay to be calibrated and execute calibration operation in reagent area interface. For specific information on ordering calibrations, refer to the calibration section of Analyzer Operating Instructions.
- Execute recalibration according to the calibration interval required in this package insert.

Quality Control

- When new lot used, check or edit the quality control information.
- Scan the control barcode, choose corresponding quality control information and execute testing. For specific information on ordering quality controls, refer to the quality control section of the Analyzer Operating Instructions.

Sample Testing

- After successfully loading the sample, select the sample in interface and edit the assay for the sample to be tested and execute testing.. For specific information on ordering patient specimens, refer to the sample ordering section of the Analyzer Operating Instructions.

To ensure proper test performance, strictly adhere to Analyzer Operating Instructions.

Calibration

Traceability: This method has been standardized against the Snibe internal reference standard.

Test of assay specific calibrators allows the detected relative light unit (RLU) values to adjust the master curve.

Recalibration is recommended as follows:

- Whenever a new lot of Reagent or Starter 1+2 is used.
- Every 7 days.
- The analyzer has been serviced.
- Control values lie outside the specified range.

Quality Control

Controls are recommended for the determination of quality control requirements for this assay and should be run in singlicate to monitor the assay performance. Refer to published guidelines for general quality control recommendations, for example Clinical and Laboratory Standards Institute (CLSI) Guideline C24 or other published guidelines⁹.

Quality control is recommended once per day of use, or in accordance with local regulations or accreditation requirements and your laboratory's quality control procedures, quality control could be performed by running the Anti-Cardiolipin IgM assay:

- Whenever the kit is calibrated.
- Whenever a new lot of Starter 1+2 or Wash Concentrate is used.

Controls are only applicable with MAGLUMI and Biolumi systems and only used matching with the same top seven LOT numbers of corresponding reagents. For each target value and range refer to the label.

The performance of other controls should be evaluated for compatibility with this assay before they are used. Appropriate value ranges should be established for all quality control materials used.

Control values must lie within the specified range, whenever one of the controls lies outside the specified range, calibration should be repeated and controls retested. If control values lie repeatedly outside the predefined ranges after successful calibration, patient results must not be reported and take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the package insert.
- If necessary, contact Snibe or our authorized distributors for assistance.
- If the controls in kit are not enough for use, please order Anti-Cardiolipin IgM (CLIA) Controls (REF: 160201437MT) from Snibe or our authorized distributors for more.

RESULTS

Calculation

The analyzer automatically calculates the aCL IgM concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in AU/mL. For further information please refer to the Analyzer Operating Instructions.

Interpretation of Results

The expected range for the aCL IgM assay was obtained by testing 117 confirmed APS patients, 93 patients with SLE and 210 apparently healthy individuals in China, gave the following expected value by ROC curve:

- Non-reactive: A result less than 20.0 AU/mL (<20.0 AU/mL) is considered to be negative.
- Reactive: A result greater than or equal to 20.0 AU/mL (≥20.0 AU/mL) is considered to be positive.

Results may differ between laboratories due to variations in population and test method. It is recommended that each laboratory establish its own reference interval.

LIMITATIONS

- Results should be used in conjunction with patient's medical history, clinical examination and other findings.
- If the aCL IgM results are inconsistent with clinical evidence, additional testing is needed to confirm the result.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with *in vitro* immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed⁹.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.

SPECIFIC PERFORMANCE CHARACTERISTICS

Representative performance data are provided in this section. Results obtained in individual laboratories may vary.

Precision

Precision was determined using the assay, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): duplicates at two independent runs per day for 5 days at three different sites using three lots of reagent kits (n = 180). The following results were obtained:

Sample	Mean (AU/mL) (n=180)	Within-Run		Between-Run		Reproducibility	
		SD (AU/mL)	%CV	SD (AU/mL)	%CV	SD (AU/mL)	%CV
Serum Pool 1	5.215	0.136	2.61	0.021	0.40	0.178	3.41
Serum Pool 2	21.401	0.782	3.65	0.234	1.09	0.977	4.57
Serum Pool 3	202.879	6.138	3.03	2.648	1.31	9.872	4.87
Plasma Pool 1	5.397	0.179	3.32	0.100	1.85	0.259	4.80
Plasma Pool 2	22.742	0.848	3.73	0.212	0.93	1.214	5.34
Plasma Pool 3	198.224	6.514	3.29	3.530	1.78	11.437	5.77
Control 1	9.999	0.259	2.59	0.105	1.05	0.337	3.37
Control 2	99.644	3.170	3.18	2.218	2.23	4.764	4.78

Linear Range

2.00-400 AU/mL (defined by the Limit of Quantitation and the maximum of the master curve).

Reportable Interval

1.00-8000 AU/mL (defined by the Limit of Detection and the maximum of the master curve*Recommended Dilution Ratio).

Analytical Sensitivity

Limit of Blank (LoB) =0.50 AU/mL.

Limit of Detection (LoD) =1.00 AU/mL.

Limit of Quantitation (LoQ) =2.00 AU/mL.

Analytical Specificity

Interference

Interference was determined using the assay, three samples containing different concentrations of analyte were spiked with potential endogenous and exogenous interferents in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Interference	No interference up to	Interference	No interference up to
Bilirubin	90 mg/dL	Rheumatoid factor	2500 IU/mL
Hemoglobin	1000 mg/dL	ANA	398 AU/mL
Intralipid	3000 mg/dL	Biotin	0.5 mg/dL
HAMA	40 ng/mL	/	/

High-Dose Hook

No high-dose hook effect was seen for aCL IgM concentrations up to 8000 AU/mL.

Method Comparison

A comparison of the Anti-Cardiolipin IgM assay with a commercially available immunoassay, gave the following correlations (AU/mL):

Number of samples measured: 120

Passing-Bablok: y=1.0075x-0.1307, r=0.970.

The clinical specimen concentrations were between 2.152 and 393.987 AU/mL.

REFERENCES

1. Bradacova P, Slavik L, Ulehova J, et al. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review[J].

Biomedicines, 2021, 9(2):166.

2. Garcia, David, Erkan, et al. Diagnosis and Management of the Antiphospholipid Syndrome Reply[J]. The New England journal of medicine, 2018.
3. Limper M, Leeuw K D, Lely A T, et al. Diagnosing and treating antiphospholipid syndrome: a consensus paper[J]. The Netherlands Journal of Medicine, 2019, 77(3):98-108.
4. Wang D, Lv W, Zhang S, et al. Advances in the Research on Anticardiolipin Antibody[J]. Journal of Immunology Research, 2019, 2019(3):1-7.
5. Miyakis S, M.D. Lockshin, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. Journal of Thrombosis and Haemostasis, 2006, 295-306.
6. Meijide H, Sciascia S, Sanna G, et al. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review[J]. Autoimmunity reviews, 2013, 12(3):421-425.
7. Lakos G, Favaloro E J, Harris E N, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies[J]. Arthritis & Rheumatism, 2012, 64(1):1-10.
8. CLSI. Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
9. Boscato L M, Stuart M C. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34(1):27-33.

SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
	Temperature limit (Store at 2-8°C)		Use-by date
	Contains sufficient for<n> tests		Keep away from sunlight
	This way up		Authorized representative in the European Community
	In vitro diagnostic medical device		Kit component
	Catalogue number		Batch code
	CE marking with notified body ID number		

MAGLUMI® and Biolumi® are trademarks of Snibe. All other product names and trademarks are the property of their respective owners.



Shenzhen New Industries Biomedical Engineering Co., Ltd.
No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China
Tel: +86-755-21536601 Fax:+86-755-28292740



Shanghai International Holding Corp. GmbH (Europe)
Eiffestrasse 80, 20537 Hamburg, Germany
Tel: +49-40-2513175 Fax: +49-40-255726